Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

BACKGROUND: The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients. METHODS: oral cyclophosphamide (Endoxan®, Baxter, Italy) was administered at the dose of 50 mg da...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Ferrandina, Gabriella, Corrado, Giacomo, Mascilini, Floriana, Malaguti, Paola, Samaritani, Riccardo, Distefano, Mariagrazia, Masciullo, Valeria, Di Legge, Alessia, Savarese, Antonella, Scambia, Giovanni
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4301460/
https://ncbi.nlm.nih.gov/pubmed/25495785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-947
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars